SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study

In clinical trials, a sofosbuvir/velpatasvir (SOF/VEL) pangenotypic single-tablet regimen was associated with high sustained virological response (SVR) rates at 12 weeks (SVR12) after the end of treatment, regardless of genotype and fibrosis stage. No real-life data on genotype 3 (GT3) cirrhotic pat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cells
Auteurs principaux: Mangia, Alessandra, Cenderello, Giovanni, Copetti, Massimiliano, Verucchi, Gabriella, Piazzolla, Valeria, Lorusso, Celeste, Santoro, Rosanna, Squillante, Maria Maddalena, Orlandini, Alessandra, Minisini, Rosalba, Ciancio, Alessia
Format: Artigo
Langue:Inglês
Publié: MDPI 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6523403/
https://ncbi.nlm.nih.gov/pubmed/30987413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells8040313
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires